Latest Hydromorphone Stories
SAN CARLOS, Calif., June 27, 2011 /PRNewswire/ -- PharmacoFore, Inc., a privately held biopharmaceutical company developing next-generation abuse-resistant prescription drugs, today announced the appointment of Dr. Joseph Stauffer as Chief Medical Officer & VP, Corporate Strategy and Dr.
CHADDS FORD, Pa., June 23, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan.
SAN CARLOS, Calif., June 23, 2011 /PRNewswire/ -- PharmacoFore, Inc., a privately held biopharmaceutical company developing next-generation abuse-resistant prescription drugs, today announced positive results from a Phase I human proof-of-concept (hPOC) study of its hydromorphone (HM) Bio-Activated Molecular Delivery(TM) (Bio-MD(TM)) product candidate, PF329.
REDWOOD CITY, Calif., May 31, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
TALLAHASSEE, Fla., April 22, 2011 /PRNewswire/ -- The Florida Society of Pain Management Providers (www.Flspmp.org) urges Government, Law Enforcement and the media to stop using false prescription drug data and statistics.
MORRISTOWN, N.J., Dec. 14, 2010 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S.
Highland Pharmaceuticals Announces New Extraction-Resistant Oral Drug Delivery System In the last twenty years, the misuse of opioid-type medications has become an alarming problem in American society.
Combination of Morphine plus Oxycodone IV Demonstrates Improved Analgesia and Tolerability Compared to IV Morphine SYDNEY and BEDMINSTER, N.J., Aug 9 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients...
BLUE BELL, Pa., June 22 /PRNewswire/ -- TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline.
According to a study by two governmental agencies, emergency room visits linked to prescription painkillers abuse have jumped 111 percent over a five-year period, a shocking increase that threatens the public health system in the United States.